By Kamal Choudhury and Christy Santhosh
(Reuters) -The U.S. Food and Drug Administration on Thursday approved Kura Oncology and Japanese partner Kyowa Kirin's once-daily pill, Komzifti, to treat a rare form of blood cancer that has returned or stopped responding to treatment.
The drug is approved for acute myeloid leukemia patients with an NPM1 mutation, a genetic change found in about 30% of cases.
Acute myeloid leukemia is an aggressive cancer of the blood and bone marrow.
Kura said the drug will be available within the next few business days at a price of $48,500 for a one-month supply.
With the approval, Kura's drug now competes with Syndax Pharmaceuticals' Revuforj, which was approved for the same indication by the FDA last month.
Komzifti’s approval comes with a boxed warning for differentiation syndrome and an additional warning for QTc interval prolongation, a delay in the heart’s electrical recovery after a beat, and potential harm to unborn babies.
A boxed warning is the U.S. Food and Drug Administration’s strongest alert for serious or life-threatening risks and appears prominently on a drug’s label to warn doctors and patients.
Revuforj carries a boxed warning for QTc interval prolongation, giving Kura “a significant competitive advantage,” according to Wedbush analysts.
Kura's Chief Medical Officer Mollie Leoni said the risk of QTc prolongation with Komzifti is low, adding it is “extraordinarily unlikely” to lead to a boxed warning.
The company said it is in dialogue with the FDA about potential steps post-approval that could help refine the labeling.
Under the terms of its collaboration with Kyowa, Kura is responsible for manufacturing Komzifti and will lead commercialization in the United States, while Kyowa handles commercial strategy and development outside the U.S.
Analysts, on average, expect Komzifti to have annual sales of $1.32 billion by 2031, according to LSEG data.
(Reporting by Kamal Choudhury and Christy Santhosh in Bengaluru; Editing by Shailesh Kuber and Tasim Zahid)
LATEST POSTS
- 1
IDF struck Iran's largest petrochemical plant, second facility hit in two days, Katz confirms - 2The most effective method to Distinguish the Best Material Organization in Your Space
- 3Little Urban areas to Visit in Western Europe
- 4Find the Keys to Fruitful Venture The board: Conveying Results on Time
- 5Cocoa Prices Undercut Amid the Prospects of Abundant Supplies
- RFK Jr. says fewer flu shots for kids may be 'better.' What experts say.
- The Manual for Well known rough terrain Vehicles
- The 10 Most Noteworthy Games in History
- Building a Maintainable Closet: Individual Excursions in Moral Style
- Burger King launches 'SpongeBob' menu ahead of film's release. A look at the Bikini Bottom-inspired meal, plus what taste testers are saying.
- A Couple of Modest Guitars for 2024
- Woman, 60, Is Finally Traveling the World Decades After Husband’s Death Held Her Back
- I’m a doctor. Here are 10 science-backed tips to help you get healthier.
- Earth’s magnetic field protects life on Earth from radiation, but it can move, and the magnetic poles can even flip
